Correlation Between Crinetics Pharmaceuticals and Alx Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Crinetics Pharmaceuticals and Alx Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Crinetics Pharmaceuticals and Alx Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Crinetics Pharmaceuticals and Alx Oncology Holdings, you can compare the effects of market volatilities on Crinetics Pharmaceuticals and Alx Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Crinetics Pharmaceuticals with a short position of Alx Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Crinetics Pharmaceuticals and Alx Oncology.

Diversification Opportunities for Crinetics Pharmaceuticals and Alx Oncology

-0.49
  Correlation Coefficient

Very good diversification

The 3 months correlation between Crinetics and Alx is -0.49. Overlapping area represents the amount of risk that can be diversified away by holding Crinetics Pharmaceuticals and Alx Oncology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alx Oncology Holdings and Crinetics Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Crinetics Pharmaceuticals are associated (or correlated) with Alx Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alx Oncology Holdings has no effect on the direction of Crinetics Pharmaceuticals i.e., Crinetics Pharmaceuticals and Alx Oncology go up and down completely randomly.

Pair Corralation between Crinetics Pharmaceuticals and Alx Oncology

Given the investment horizon of 90 days Crinetics Pharmaceuticals is expected to under-perform the Alx Oncology. But the stock apears to be less risky and, when comparing its historical volatility, Crinetics Pharmaceuticals is 2.19 times less risky than Alx Oncology. The stock trades about -0.15 of its potential returns per unit of risk. The Alx Oncology Holdings is currently generating about 0.39 of returns per unit of risk over similar time horizon. If you would invest  1,102  in Alx Oncology Holdings on January 30, 2024 and sell it today you would earn a total of  597.29  from holding Alx Oncology Holdings or generate 54.2% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy100.0%
ValuesDaily Returns

Crinetics Pharmaceuticals  vs.  Alx Oncology Holdings

 Performance 
       Timeline  
Crinetics Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Crinetics Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.
Alx Oncology Holdings 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Alx Oncology Holdings are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Alx Oncology displayed solid returns over the last few months and may actually be approaching a breakup point.

Crinetics Pharmaceuticals and Alx Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Crinetics Pharmaceuticals and Alx Oncology

The main advantage of trading using opposite Crinetics Pharmaceuticals and Alx Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Crinetics Pharmaceuticals position performs unexpectedly, Alx Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will offset losses from the drop in Alx Oncology's long position.
The idea behind Crinetics Pharmaceuticals and Alx Oncology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Other Complementary Tools

Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Valuation
Check real value of public entities based on technical and fundamental data